β-casein blood-pressure peptide
A natural peptide that blocks ACE, the enzyme that raises blood pressure, helping to lower it, studied as a potential treatment, experimental and not yet an approved drug.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
What if a peptide thought to block a blood-pressure enzyme is actually working through a completely different route in the body?
If this is correct, the peptide carries opioid-like risks such as tolerance and nervous system effects that standard blood pressure drugs do not, and combining it with opioid-blocking medications could make it stop working entirely. Doctors, formulators, and anyone using it as a supplement would need to think about it very differently.
Could a single small change to a milk-derived peptide make it stable enough to actually work as an oral blood pressure treatment?
If this holds, a cheap, targeted modification could transform a peptide that enzymes in the gut quickly destroy into a viable oral treatment candidate, without the expensive redesign usually required to make peptides last. That could lower the development cost and regulatory hurdle for food-derived blood pressure ingredients.
Could a peptide taken for blood pressure also benefit people with insulin resistance or chronic inflammation by changing their gut microbiome?
If the peptide shifts gut bacteria toward types that produce beneficial short-chain fatty acids, it could help a much broader group: people with metabolic syndrome who may not even have high blood pressure. That would open the door to using it as a functional food ingredient rather than a narrowly targeted drug.
What if a peptide works by triggering a nerve reflex in the gut wall rather than by traveling through the bloodstream to its target?
If the active site is in the gut lining rather than the circulation, then getting the peptide absorbed intact becomes the wrong goal entirely. It would mean the focus should shift to protecting the peptide from stomach acid long enough to reach the intestine, which changes how supplements and drugs made from it would need to be designed and packaged.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.30392834544181824 | boltz-2 |
| ranking score | 0.7480877041816711 | boltz-2 |
▸3-letter notation
▸recipeboltz-2 1.0
| parameter | value |
|---|---|
| model | boltz-2 1.0 |
| weights | — |
| hardware | nvidia_nim_api |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | colabfold_nvidia |
| diffusion samples | 1 |
| runtime | — |
| predicted by | mlx@peptide |
| predicted at | 2026-04-25 |
▸citationbibtex
@peptide{pep04525,
sequence = {KYPVQPFTESQSLTL},
target = {ace},
author = {peptidemodel},
year = {2026},
status = {computed}
}